The US FDAhas granted orphan status to Angioblast Systems' allogeneic mesenchymal precursor cell therapy for use in cancer patients receiving bone marrow transplants. The non-patient-specific cells will be used to regenerate damaged bone marrow and help transplants engraft in cases of insufficient haematopoietic stem cell production in patients with haematologic malignancies who have failed conventional chemotherapy. Angioblast is 39% owned by the Australian firm Mesoblast, which is developing various stem cell-based therapies (Scrip Online, August 18th, 2008).
US orphan status for Angioblast's stem cell therapy
The US FDAhas granted orphan status to Angioblast Systems' allogeneic mesenchymal precursor cell therapy for use in cancer patients receiving bone marrow transplants. The non-patient-specific cells will be used to regenerate damaged bone marrow and help transplants engraft in cases of insufficient haematopoietic stem cell production in patients with haematologic malignancies who have failed conventional chemotherapy. Angioblast is 39% owned by the Australian firm Mesoblast, which is developing various stem cell-based therapies (Scrip Online, August 18th, 2008).
More from Anticancer
• By
The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.
• By
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
• By
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
• By
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
More from Therapeutic Category
• By
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
• By
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
• By
Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.